N/A N=1,457 PROPPER Prospective Registry of Outcomes With Penile Prosthesis
Erectile Dysfunction · Impotence
Primary: Number of Participants With Penile Prosthesis Overall Subject Satisfaction — 34; 34; 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=104 Improving Cancer On-treatment Symptom Management
Cancer · Thoracic Neoplasms · Gastrointestinal Cancer
Primary: Participants With Change in Their Physician-assessed Burden Score — 43; 32; 25 Participants
N/A N=504 Protecta Smart Analysis Register
Patients With an Indication for an ICD Implantation According to the Guidelines
Primary: Analysis of Change of Episodes Inappropriately Treated by Shock Therapy Due to Smart Shock™ Technology. — 94.9 % of episodes wo shock due to SmartShock
Phase 4 N=108 Pitocin or Oral Misoprostol for PROM IOL
PROM
Primary: Time From Induction of Labor (IOL) to Delivery — 18.1; 14.9 Hours
N/A N=87 Multicenter Clinical Observation PROMOS®
Primary and Secondary Omarthrosis
Primary: Radiological and Clinical Loosening Rates of the Glenoid and Humeral Components — 96.29 Percentage survivorship
N/A N=230 Cervical Ripening in Premature Rupture of Membranes
Pregnancy · Premature Rupture of Membranes · Preterm Premature Rupture of Membranes
Primary: Rate of Cesarean Section — 27; 26; 89; 86 participants — p=0.99
Early Phase 1 N=34 PRevention Of Methamphetamine Use Among Postpartum Women Trial (PROMPT)
Methamphetamine-dependence · Postpartum Abstinence
Primary: Successful Recruitment and Randomization of 40 Postpartum Women Into the PROMPT Study — 16; 14; 2; 2 Participants
Phase 2 N=21 Progesterone for the Management of Preterm, Premature Rupture of the Membranes: A Randomized Controlled Trial.
Pregnancy Complications
Primary: Number of Participants With Achievement of 34 Weeks Gestation — 0; 0 Participants
N/A N=300 PROMIS Measures in Primary Care Practice
Sleep · Pain · Anxiety
Primary: Change From Baseline in PROMIS Composite T-Score at 3-Month Follow-up — 3.48; 2.38 T-score — p=0.165
Phase 4 N=2,681 PROMUS Element Plus US Post-Approval Study
Coronary Artery Disease
Primary: Cardiac Death or Myocardial Infarction Rate in PLATINUM-like Patients — 1.78 percentage of patients — p=<.0001
N/A N=100 PROLONG Prospective, Multi-center, Open-label, Post-market Study
Chronic Pain
Primary: Mean Change in Pain Assessed by Numerical Rating Scale (NRS) From Baseline to 3 Months — 2.3; 3.3 score on a scale
N/A N=995 Neonatal Outcome by Reason for Delivery
Preterm Delivery
Primary: Composite Perinatal Morbidity — 277; 203; 221; 45 participants
N/A N=110 Patient-Reported Outcomes Measurement Information System Integration Into Rheumatology Clinical Practice
Rheumatic Diseases
Primary: Percent of Appointments at Which Patient-Reported Outcomes Measurement Information System (PROMIS) Scores Are Documented in the Electronic Medical Record (EMR) Note by…
N/A N=312 PRogram In Support of Moms: An Innovative Stepped-Care Approach for Obstetrics and Gynecology Clinics
Depression
Primary: Change in Edinburgh Postnatal Depression Scale Score (EPDS) — -4.3; -4.2 score on a scale
N/A N=288 Analysis of ROM Plus to Detect Rupture of Membranes
Rupture of Amniotic Membranes
Primary: Pregnant Women Positive and Negative for Membrane Rupture Measured Via Clinical Assessment, Chart Review and ROM Plus — 95; 88; 160; 187 participants
N/A N=246 P3 (Prepared, Protected, emPowered)
Sexually Transmitted Diseases · Safe Sex · Adherence, Medication
Primary: PrEP Adherence Defined by Tenofovir Diphosphate (P3 and P3+ vs Control) — 24; 33; 23; 18 Participants — p=0.04965
N/A N=141 Program Reinforcement Impacts Self Management (PRISM)
Diabetes Mellitus
Primary: Hemoglobin A1C (HbA1C, %) — 6.8; 7.6; 6.8; 7.1 percentage of glycosolated hemoglobin
Phase 3 N=152 Progesterone (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM)
Preterm Delivery
Primary: Gestational Age at Delivery — 29.2; 29.5 weeks.
N/A N=2,009 XIENCE V/PROMUS Everolimus-Eluting Stent System Post-marketing Surveillance Protocol for Japan
Angina · Chronic Coronary Occlusion · Stent Thrombosis
Primary: Number of Participants With Stent Thrombosis (ST) as Per ARC Definition — 6; 2; 6 participants
Phase 2 N=30 Pediatric Radiation Oncology With Movie Induced Sedation Effect (PROMISE)
Pediatric Cancer
Primary: Percentage of Pediatric Patients Age 3-7 Who Require Daily General Anesthesia for All Treatments — 88; 12 percentage of participants
N/A N=221 ProMRI Study of the Entovis Pacemaker System (Phase B)
Magnetic Resonance Imaging (MRI); Cardiac Pacing
Primary: MRI and Pacing System Related Serious Adverse Device Effect (SADE) Free Rate — 99.5 percentage of participants
N/A N=110 Prometra's Utilization in Mitigating Pain (PUMP)
Intractable Pain
Primary: Demonstrate That Prometra Programmable Pump System Accurately and Safely Delivers Medication in the Intrathecal Space, as Programmed. — 97.8 % of programmed vol…
N/A N=229 ProMRI Study of the Entovis Pacemaker System
Safety of the ProMRI Pacemaker System Under Specific MRI Conditions
Primary: MRI and Pacing System Related Serious Adverse Device Effect (SADE) Free Rate — 100 percentage of participants
N/A N=129 Evaluation of CRB in PROM Patients
Premature Rupture of Fetal Membranes
Primary: Time of Labor — 850.4; 1016.6 Minutes
Phase 3 N=200 Prostin and Propess in Induction of Labor
Labor Pain
Primary: Induction to Delivery Interval — 22.3; 21.2 hours
N/A N=426 TARGET Post-Approval Study
Complex Regional Pain Syndrome (CRPS)
Primary: Rate of Serious Adverse Events (SAEs) — 8.7 percentage of events
N/A N=10,256 Symptom Management Implementation of Patient Reported Outcomes in Oncology
Other Cancer · Gastrointestinal Cancer · Thoracic Cancer
Primary: Emergency Department Treat/Release [EDTR] Event Occurrence Status at Day 30 — 5.8; 6.9; 5.3; 5.8 percentage of patients with event — p=0.214
N/A N=50,458 Primary Palliative Care for Emergency Medicine (PRIM-ER)
Emergencies
Primary: Acute Care Admission — 0.644; 0.613 Proportion of participants
Phase 3 N=100 A Prospective, Multi-center Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element™)
Atherosclerosis · Coronary Artery Disease
Primary: Cardiac Events (Composite) — 1.0 percentage of participants
Phase 3 N=680 Pragmatic, Randomized Optimal Platelet and Plasma Ratios
Trauma
Primary: 24-hour Mortality — 43; 58 participants — p=0.12